Skip to main content
. 2021 Nov 2;18(1):1–14. doi: 10.1080/21645515.2021.1976581

Table 3.

GMTs, GMFR, and proportion of participants with ≥4-fold rise in serotype-specific OPA antibodies from pre-vaccination to 30 days after vaccination with V114

Serotype Outcome Concomitant (N = 599)
Non-concomitant (N = 598)
n Response 95% CI n Response 95% CI
1 GMT (Day 1) 559 12.4 11.0–14.1 549 12.3 10.9–14.0
GMT (Day 30) 551 141.5 120.9–165.5 523 209.1 178.1–245.5
GMFR 517 8.0 6.8–9.3 505 11.8 10.1–13.9
≥4-fold rise, % (n) 517 57.8 (299) 53.4–62.1 505 66.3 (335) 62.0–70.5
3 GMT (Day 1) 546 19.9 18.2–21.9 538 20.3 18.4–22.4
GMT (Day 30) 540 137.3 123.0–153.2 521 148.2 132.7–165.4
GMFR 495 4.7 4.3–5.3 493 4.8 4.3–5.4
≥4-fold rise, % (n) 495 54.7 (271) 50.2–59.2 493 54.8 (270) 50.3–59.2
4 GMT (Day 1) 519 67.5 58.0–78.4 524 66.2 56.8–77.0
GMT (Day 30) 543 910.3 796.1–1,040.9 513 1,074.4 926.7–1,245.5
GMFR 471 9.4 8.0–11.0 476 11.5 9.7–13.6
≥4-fold rise, % (n) 471 63.1 (297) 58.5–67.4 476 66.4 (316) 61.9–70.6
5 GMT (Day 1) 560 33.6 29.8–38.0 547 33.0 29.1–37.4
GMT (Day 30) 549 402.1 342.0–472.7 523 494.4 419.2–583.0
GMFR 516 8.1 7.0–9.4 503 10.2 8.7–12.0
≥4-fold rise, % (n) 516 60.5 (312) 56.1–64.7 503 63.4 (319) 59.0–67.6
6A GMT (Day 1) 498 366.4 325.4–412.6 499 426.1 376.5–482.2
GMT (Day 30) 526 5,419.5 4,759.9–6,170.5 513 6,812.6 5,998.4–7,737.3
GMFR 443 10.5 9.1–12.1 451 12.1 10.5–14.0
≥4-fold rise, % (n) 443 71.1 (315) 66.6–75.3 451 75.6 (341) 71.4–79.5
6B GMT (Day 1) 512 157.5 131.7–188.3 524 166.9 139.7–199.5
GMT (Day 30) 539 3,912.9 3,456.6–4,429.5 520 4,408.7 3,870.5–5,021.7
GMFR 466 17.6 14.8–20.9 481 20.5 17.3–24.4
≥4-fold rise, % (n) 466 72.5 (338) 68.2–76.5 481 76.1 (366) 72.0–79.8
7F GMT (Day 1) 535 301.4 256.6–354.1 520 418.9 353.6–496.3
GMT (Day 30) 545 3,469.7 3,148.8–3,823.2 524 4,244.0 3,799.0–4,741.1
GMFR 492 9.2 7.9–10.8 484 8.0 6.9–9.4
≥4-fold rise, % (n) 492 63.0 (310) 58.6–67.3 484 59.7 (289) 55.2–64.1
9V GMT (Day 1) 540 384.8 341.2–434.0 528 450.8 396.6–512.3
GMT (Day 30) 534 2,831.9 2,560.8–3,131.7 521 2,900.8 2,592.6–3,245.8
GMFR 483 5.8 5.1–6.6 483 5.3 4.6–6.1
≥4-fold rise, % (n) 483 54.9 (265) 50.3–59.4 483 53.4 (258) 48.9–57.9
14 GMT (Day 1) 542 440.3 379.2–511.3 540 475.5 407.3–555.2
GMT (Day 30) 545 2,021.1 1,777.9–2,297.6 518 2,258.4 1,982.4–2,572.9
GMFR 498 3.9 3.3–4.4 491 4.1 3.5–4.7
≥4-fold rise, % (n) 498 38.6 (192) 34.3–43.0 491 40.9 (201) 36.6–45.4
18C GMT (Day 1) 545 226.9 200.7–256.4 535 246.3 217.8–278.5
GMT (Day 30) 549 3,000.9 2,686.1–3,352.6 522 3,807.1 3,402.5–4,259.8
GMFR 503 9.8 8.6–11.2 491 11.6 10.0–13.4
≥4-fold rise, % (n) 503 67.4 (339) 63.1–71.5 491 70.3 (345) 66.0–74.3
19A GMT (Day 1) 533 480.2 418.5–550.9 522 580.1 509.8–660.2
GMT (Day 30) 538 3,158.2 2,872.4–3,472.3 518 3,884.3 3,516.1–4,291.1
GMFR 482 6.2 5.4–7.2 476 6.6 5.7–7.6
≥4-fold rise, % (n) 482 53.7 (259) 49.2–58.3 476 57.1 (272) 52.6–61.6
19F GMT (Day 1) 534 394.9 349.6–446.1 536 463.7 409.9–524.5
GMT (Day 30) 547 2,462.4 2,222.2–2,728.7 522 2,518.7 2,261.9–2,804.6
GMFR 490 5.2 4.6–5.9 492 4.7 4.2–5.4
≥4-fold rise, % (n) 490 53.7 (263) 49.1–58.2 492 48.8 (240) 44.3–53.3
22F GMT (Day 1) 481 101.5 81.2–126.8 490 100.4 80.0–125.8
GMT (Day 30) 543 2,250.0 1,974.7–2,563.8 516 2,900.1 2,535.5–3,317.3
GMFR 438 15.9 12.8–19.8 446 20.6 16.4–25.9
≥4-fold rise, % (n) 438 64.2 (281) 59.5–68.7 446 67.5 (301) 62.9–71.8
23F GMT (Day 1) 471 110.2 93.3–130.1 473 165.7 138.3–198.6
GMT (Day 30) 540 2,130.1 1,853.1–2,448.4 519 2,714.1 2,360.1–3,121.2
GMFR 427 13.9 11.7–16.6 436 11.9 9.9–14.3
≥4-fold rise, % (n) 427 73.1 (312) 68.6–77.2 436 67.2 (293) 62.6–71.6
33F GMT (Day 1) 555 1,791.9 1,581.0–2,030.9 537 2,131.4 1,880.8–2,415.4
GMT (Day 30) 547 7,879.3 7,041.9–8,816.4 518 10,077.9 8,946.7–11,352.2
GMFR 510 4.3 3.8–4.9 488 4.6 4.0–5.3
≥4-fold rise, % (n) 510 44.1 (225) 39.8–48.5 488 44.9 (219) 40.4–49.4

CI, confidence interval; GMFR, geometric mean fold rise; GMT, geometric mean titer; OPA, opsonophagocytic activity; V114, 15-valent pneumococcal conjugate vaccine. Within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution for continuous endpoints and using the exact binomial method proposed by Clopper and Pearson for dichotomous endpoints.